...still over 9 million shares short - 25% of float.
I'm begging you to give it a rest. Ampion will prove to be superior to all the BS you post, and the market opportunity will be much greater than what you want to believe. Why do you continue to reference research from CITI that is stale and now irrelevant? Is it not obvious that Ampion MI has much greater efficacy than Ampion SI, and represents a vastly greater revenue opportunity, Ben Gay? Then you reference Jefferies, who basically pulled a chew and screw on AMPE, taking the secondary fees and belatedly coming out with a perfunctory and shallow research report to fulfill their obligation to initiate coverage. After the STEP failure, we never heard from them again. No surprise there. Again, we will see who is right and who is wrong. In the interim, stop posting your BS to a Board that mostly is unable to distinguish fact from your fiction.
You're an idiot to reference Citi & Jefferies research that is beyond stale - Jefferies hasn't written a note since STEP failure, and Citi hasn't since last Fall, and that analyst is now with Barclays. Not to mention those reports were written before the STRIDE trial with its MI regimen. "This is valued with HA's", I don't think so, Ben Gay. We will see who is right. In the interim, why don't you just sell, put yourself out of your misery, and get lost.
Oh, by the way, how's that OHRP investment working for you? Makes me nervous to think that I am investing along side you.
In past conversations with MM regarding OAK, his constant refrain was that "nothing works" in terms of treatments, and that includes Synvisc. No to mention it is starting to lose reimbursement. You can deduce that Synvisc will be obsoleted quickly if Ampion is approved. Then you can take the market for Synvisc and multiply that by 2 or 3 times given that there is huge OAK population for which Synvisc either doesn't work or isn't prescribed for.
That is why is see Ampion as a blockbuster. Blockbuster drugs are rare and don't come around very often. What is Pharma willing to pay for that?
....IF STRIDE mirrors STRUT, then you have a drug for OAK(a huge market that is growing every year with an unmet medical need for K-4's) that is unprecedented for pain relief & duration of action. Factor in the huge margins and 2 or 3 injections per year/patient, and it is not hard to see this as a $Billion drug. Then consider that Ampion could, in a relatively short period of time, be approved for other indications for other joints. Then maybe its a Multi $Billion drug.
What is Pharma willing to pay for that? Given the deals that have already transpired in the industry, $40.00 is a possibility.
..he is a wolf in a sheep's outfit, a short posing as a long. He has NEVER once posted anything regarding Ampion upside....just cut & paste articles ad nauseum whose aim is to continually cast doubt on Ampion.
And he talks about a "window of opportunity"?? Give me a break.
...most have some analyst coverage if they are public companies. We have the unique distinction of no analyst coverage at the moment.
Just means that if results are good, more powder for the stock to explode to the upside as there is, IMHO, a huge valuation discrepancy/pricing disconnect in AMPE.
ZERO analyst coverage, little institutional presence and thin float makes for anemic trading volume.
AMPE is beyond below the radar screen of Wall Street. If results are good, this thing will absolutely rocket higher, and then keep going as Wall Street wakes up to the story.
...shorts were given an opportunity to knock it around with no volume.
Results can't come soon enough.
Yes, a few professionals, and that is NOT you. End of April or beginning of May. Maybe one day you should pick up the phone and do some real research instead of your BS cut & paste.
Sorry Ben Gay, but wrong AGAIN. Maybe you ought to do a little more research - results end of this month or 1st half of May.
.....much more to come! Wall Street is asleep to the blockbuster potential of Ampion.
..there is a pattern that recurs of the share price pushed down in the first half hour of trading. I feel it is manipulation and shorting as opposed to profit taking. As I've posted before, with thin trading volume, a small float, no analyst coverage and minor institutional support, the stock is very easily pushed around.
All that will change after STRIDE.